Fortive Corporation

FTV · NYSE · USD

Can Fortive keep core growth accelerating after its spin-off, or was the recent pickup helped by easy comparisons, extra selling days and a few strong brands?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Post-spin portfolio focus

    The bull case is that a simpler two-segment Fortive is putting money and management attention behind its strongest brands, and order growth shows the strategy is landing.

  • Data center product pull-through

    New products aimed at data center build-outs and maintenance pull through older Fluke lines, which bulls see as durable demand rather than a one-quarter spike.

  • Cost cuts recycled into growth

    Costs taken out of corporate and segment structures are being reinvested in selling and product development while buybacks shrink the share count and lift per-share profit.

  • Deferred hospital orders released

    Hospital equipment orders held back through the reimbursement changes are starting to be released, which the bull case needs for the healthcare segment to keep growing.

Bear case

  • Acceleration flattered by comparisons

    The bear case is that recent core growth leaned on extra selling days and easy comparisons, and the back half of the year tests the true underlying rate.

  • Buybacks outpace cash flow

    Repurchases have been funded partly with short-term borrowings, so the per-share lift depends on free cash flow holding up while spending on growth rises.

  • Tariff and product mix drag

    Tariffs and a shift toward lower-margin products have held gross margin down, so operating gains rest on cost cuts rather than on the mix of what is sold.

  • AI and software disruption

    The bear case worries that AI could erode the value of Fortive's mission-critical software brands, and that customers or rivals could build similar tools themselves.

Bull and bear points

Growth & Execution

In short: Core growth keeps accelerating, while hospital equipment budgets and government procurement remain unreliable.

Bull · 2

  • Guidance raised on orders running ahead of revenue

    Management raised both its core growth and earnings outlook after four quarters of acceleration, so the plan now assumes improving demand rather than a stable market.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • Fluke data center product pulls through the portfolio

    Data centers were always a Fluke end market, but a new fiber tester is winning commissioning work and dragging power, battery and calibration tools along with it.

    Q2 FY2026 call
Bear · 2

  • Gordian growth depends on state and local budgets

    The procurement and estimating software business sells to government agencies whose funding is set by policy, and June fiscal year-end concentrates the year into one quarter.

    Q3 FY2025 call

  • Hospital capital equipment demand stays cautious

    Low-temperature sterilization equipment is sold to hospitals that defer discretionary purchases when reimbursement rules are unsettled, which makes that revenue hard to forecast.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Margins and cash conversion are improving, while tariffs, product mix and borrowing costs weigh on gains.

Bull · 2

  • Operating leverage lifts operating margin

    Cost cuts and higher volume are dropping through to profit, and management still commits to expanding adjusted EBITDA margin every year at the upper end of its framework.

    Filed financials

  • Capital-light cash generation funds the plan

    Fortive spends little on plants relative to sales and converts most of its profit into cash, so buybacks and small acquisitions can be paid for out of operations.

    Filed financials
Bear · 2

  • Buybacks and dividends exceed free cash flow

    Returning more cash than the business generates means buybacks have been partly funded with short-term borrowings, which adds interest cost if cash flow dips.

    Filed financials

  • Tariffs and mix keep gross margin from expanding

    Tariff costs are only fully offset below the gross margin line, and faster growth in lower-margin products in both segments works against the margin framework.

    Q1 FY2026 call

Market Position

In short: Fluke's brand supports pricing power, while weak European demand and tariff policy sit outside its control.

Bull · 2

  • Pricing covers cost increases on differentiated products

    Price more than covered cost increases in the first quarter, which management reads as proof that Fluke and ASP hold enough pricing power to absorb inflation and tariffs.

    Q1 FY2026 call

  • FDA clearance widens STERRAD into robotic surgery

    A clearance to sterilize loads up to 50 pounds makes the low-temperature system usable for robotic instruments, expanding the hospital accounts it can sell into.

    Q2 FY2026 call
Bear · 2

  • European demand weakened after stabilizing

    Management first described Europe as stabilizing and then reported a decline there, so a region that is roughly a large slice of sales is dragging on consolidated growth.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • AI could undercut the software brands

    The mission-critical software businesses face questions about whether AI makes their workflows easier to replicate, and the annual report flags legal and competitive exposure from AI use.

    10-K, filed 2026-02-25